A Phase 2, Open-label Study to Investigate the Efficacy and Safety of Ledipasvir/Sofosbuvir Fixed Dose Combination in the Treatment of Hepatitis C Virus (HCV) Infection in Pediatric Subjects Undergoing Cancer Chemotherapy
Phase of Trial: Phase II
Latest Information Update: 06 Jul 2017
At a glance
- Drugs Ledipasvir/sofosbuvir (Primary)
- Indications Hepatitis C
- Focus Adverse reactions; Therapeutic Use
- Acronyms Egypt Peds
- Sponsors Gilead Sciences
- 28 Jun 2017 Planned End Date changed from 1 Jul 2018 to 1 Apr 2019.
- 28 Jun 2017 Planned primary completion date changed from 1 Apr 2018 to 1 Jan 2019.
- 09 Dec 2016 Planned End Date changed from 1 Feb 2018 to 1 Jul 2018.